ReviewCurrent oncology reports2019
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.Journal of neuro-oncology · 2022Pooled it
- Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.BioMed research international · 2021Pooled it
- The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.BioMed research international · 2020Pooled it
- Navigating the Ethereal Tightrope: The Nanogenerator Manipulates Neurons for Immune Equilibrium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.Nature reviews. Cancer · 2025Review
- Multidisciplinary intervention for adverse events associated with ATZ + BEV therapy: a case report.Journal of pharmaceutical health care and sciences · 2025Article
- Review
- Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab.Internal medicine (Tokyo, Japan) · 2024Article
- Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.Journal of neurology · 2024Review
- Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events.Frontiers in immunology · 2024Review
- Immune-Related Peripheral Neuropathy Associated with Immune Checkpoint Inhibitors: Case Report and Review of Literature.Case reports in oncological medicine · 2024Article
- Nerve Ultrasound of Peripheral Nerves in Patients Treated with Immune Checkpoint Inhibitors.Medicina (Kaunas, Lithuania) · 2023Article
- Review
- Non-cellular immunotherapies in pediatric central nervous system tumors.Frontiers in immunology · 2023Review
- Atezolizumab-associated encephalitis in metastatic breast cancer: A case report.Oncology letters · 2022Article
- The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.International journal of molecular sciences · 2022Article
- Update on Toxic Neuropathies.Current treatment options in neurology · 2022Article
- Multi-target combinatory strategy to overcome tumor immune escape.Frontiers of medicine · 2022Review
- Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer.Investigational new drugs · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review highlights the spectrum of neurologic adverse events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the treatments undertaken, and the clinical outcomes. RECENT
findingsThe advent of ICIs has revolutionized cancer therapy. Neurologic adverse events (NAEs) are rare but clinically significant complication of ICIs. They can involve both the central and peripheral nervous system. Examples include myositis, neuropathy, encephalopathy, and myasthenia gravis. Treatment consists of holding the ICI, administration of corticosteroids, and other immunomodulatory agents as needed. The outcomes are generally favorable; however, rarely severe events can lead to significant morbidity and even mortality. Identifying and treating the range of neurologic adverse events that may potentially arise with ICIs is very important as the oncologic indications for their use continues to expand.
Indexed as
Identifiers
31776691What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.